Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Huperzine A - Supernus Pharmaceuticals

Next Previous
Drug Profile

Huperzine A - Supernus Pharmaceuticals

Alternative Names: BIS-001; BIS-001ER; INS-001; SPN 817

Latest Information Update: 05 Sep 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Harvard University
  • Developer Biscayne Pharmaceuticals; Supernus Pharmaceuticals
  • Class Alkaloids; Antiepileptic drugs; Neuroprotectants; Nootropics; Sesquiterpenes; Small molecules
  • Mechanism of Action Acetylcholinesterase inhibitors; NMDA receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Lennox-Gastaut syndrome; Dravet syndrome
  • New Molecular Entity No

Highest Development Phases

  • Phase III Seizures
  • Phase II Epilepsy; Partial epilepsies
  • No development reported Dravet syndrome

Most Recent Events

  • 30 Jul 2025 Phase-III clinical trials in Seizures (Treatment-resistant) in USA (unspecified route) (NCT07141329)
  • 28 Jun 2025 No recent reports of development identified for phase-I development in Epilepsy(In volunteers) in United Kingdom (PO)
  • 30 Dec 2024 Phase-II clinical trials in Seizures (Treatment-resistant) in USA (unspecified route) (NCT06798896)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top